GlassScriptPhysician profile
Anil R Modi
NPI 1508868704
$12,069.12
in general payments reported to CMS, 2019-2025
65 companies · $1,424 in 2025
The $1,424 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,505 · 2020: $1,523 · 2021: $1,974 · 2022: $1,631 · 2023: $1,838 · 2024: $2,175 · 2025: $1,424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,437.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,436.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $975.06 | 2019-2025 | Mounjaro, Emgality, Amyvid |
| Abbvie INC. | $846.20 | 2019-2025 | |
| Novo Nordisk INC | $761.50 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $701.91 | 2019-2025 | Repatha, Otezla, Otezla |
| Astrazeneca Pharmaceuticals LP | $687.39 | 2019-2025 | Farxiga, Breztri |
| Pfizer INC. | $595.31 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $470.58 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $415.47 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $390.71 | 2019-2025 | Jardiance |
| Abbott Laboratories | $374.05 | 2019-2025 | Freestyle Libre 3 |
| Scilex Pharmaceuticals INC. | $365.80 | 2019-2025 | Ztlido |
| Sanofi-Aventis U.S. LLC | $329.51 | 2019-2023 | |
| Shield Therapeutics INC | $311.96 | 2022-2025 | Accrufer |
| Biogen, INC. | $286.50 | 2020-2025 | Vumerity, Avonex, Tysabri |
| Greenwich Biosciences, INC. | $282.40 | 2019-2021 |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $261.45 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $222.79 | 2023-2025 | Rexulti, Nuedexta |
| Eisai INC. | $190.88 | 2021-2025 | |
| Sk Life Science, INC. | $184.42 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $164.41 | 2022 | |
| Amneal Pharmaceuticals LLC | $160.02 | 2019-2025 | Crexont |
| Lundbeck LLC | $152.77 | 2022-2024 | Vyepti, Rexulti |
| Neurocrine Biosciences, INC. | $148.22 | 2024-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $146.38 | 2019-2021 | |
| Glaxosmithkline, LLC. | $145.83 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Axsome Therapeutics, INC. | $145.06 | 2023-2025 | Sunosi |
| Teva Pharmaceuticals USA, INC. | $125.76 | 2020-2025 | Austedo Xr, Austedo Xr |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $124.06 | 2019-2022 | |
| Esperion Therapeutics, INC. | $120.47 | 2021-2024 | Nexletol |
| Csl Behring | $118.32 | 2019-2025 | Hizentra |
| Biohaven Pharmaceuticals, INC. | $117.75 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $113.75 | 2024-2025 | Hyqvia, Trintellix |
| Ucb, INC. | $109.92 | 2019-2024 | Nayzilam, Briviact |
| Avanir Pharmaceuticals, INC. | $106.59 | 2020-2022 | |
| Amarin Pharma, INC. | $105.49 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $99.20 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $85.53 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $83.12 | 2020-2022 | |
| Allergan, INC. | $82.55 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $78.24 | 2019-2024 | Ultomiris |
| Xeris Pharmaceuticals, INC. | $77.73 | 2021-2023 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $76.65 | 2019-2021 | |
| Argenx US, INC. | $68.60 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Alfasigma USA, INC. | $64.28 | 2020-2022 | |
| Idorsia Pharmaceuticals US INC | $55.63 | 2022-2023 | Quviviq |
| Grifols USA, LLC | $52.60 | 2023-2025 | Gamunex-C |
| Ani Pharmaceuticals, INC. | $51.80 | 2024-2025 | Purified Cortrophin Gel |
| Emd Serono, INC. | $51.56 | 2019-2025 | |
| Upsher-Smith Laboratories LLC | $49.81 | 2021-2022 | |
| Horizon Therapeutics Plc | $38.61 | 2023 | Krystexxa |
| Neurelis, INC. | $36.95 | 2023 | Valtoco |
| Ironwood Pharmaceuticals, INC | $33.84 | 2020 | |
| Zyla Life Sciences, INC. | $28.76 | 2019 | |
| Acorda Therapeutics, INC | $25.30 | 2020 | |
| Mallinckrodt Enterprises LLC | $25.16 | 2019 | |
| Catalyst Pharmaceuticals, INC. | $22.37 | 2023 | Firdapse |
| Ge Healthcare | $19.38 | 2019 | |
| Kyowa Kirin, INC. | $17.08 | 2019 | |
| Mylan Specialty L.P. | $16.61 | 2024 | Yupelri |
| Livanova USA, INC. | $16.05 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
| Supernus Pharmaceuticals, INC. | $15.74 | 2022 | |
| Mdd US Operations, LLC | $14.33 | 2019 | |
| Strongbridge US INC. | $11.62 | 2020 | |
| Arbor Pharmaceuticals, INC. | $11.33 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anil Modi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.